Nephros (NASDAQ:NEPH) Trading Up 0.7%

Shares of Nephros, Inc. (NASDAQ:NEPH) were up 0.7% on Wednesday . The stock traded as high as $2.09 and last traded at $2.08. Approximately 1,769 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 17,031 shares. The stock had previously closed at $2.06.

Analyst Ratings Changes

Separately, Benchmark reissued a “speculative buy” rating and issued a $5.00 target price on shares of Nephros in a research note on Wednesday, May 15th.

Nephros Trading Up 0.7 %

The stock’s 50 day moving average price is $2.17 and its 200 day moving average price is $2.69. The company has a market cap of $21.87 million, a price-to-earnings ratio of -14.82 and a beta of 1.19.

Nephros (NASDAQ:NEPH) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) EPS for the quarter. Nephros had a negative net margin of 10.23% and a negative return on equity of 17.01%. The company had revenue of $3.52 million for the quarter.

Insider Activity

In related news, CEO Robert R. Jr. Banks acquired 50,000 shares of the company’s stock in a transaction dated Thursday, May 16th. The stock was bought at an average price of $2.24 per share, with a total value of $112,000.00. Following the purchase, the chief executive officer now directly owns 70,000 shares in the company, valued at approximately $156,800. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders purchased a total of 55,000 shares of company stock valued at $123,160 in the last 90 days. 4.10% of the stock is currently owned by insiders.

Institutional Trading of Nephros

A hedge fund recently bought a new stake in Nephros stock. Mesirow Financial Investment Management Inc. bought a new position in shares of Nephros, Inc. (NASDAQ:NEPH) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 15,383 shares of the company’s stock, valued at approximately $34,000. Mesirow Financial Investment Management Inc. owned approximately 0.15% of Nephros as of its most recent filing with the Securities and Exchange Commission. 41.10% of the stock is owned by hedge funds and other institutional investors.

About Nephros

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.